Navigation Links
A Phase IIa Interferon Free Combination Hepatitis C Trial of Simeprevir (TMC435) and TMC647055 Will Commence Shortly
Date:9/19/2012

esponder patients chronically infected with HCV genotype 1a.

Additional information about this study will be posted on http://www.clinicaltrials.gov

About Medivir

Medivir is an emerging research-based pharmaceutical company focused on infectious diseases. Medivir has world class expertise in polymerase and protease drug targets and drug development which has resulted in a strong infectious disease R&D portfolio. The Company's key pipeline asset is simeprevir (TMC435), a novel protease inhibitor in phase III clinical development for hepatitis C that is being developed in collaboration with Janssen Research & Development Ireland.

In June 2011, Medivir acquired the specialty pharmaceutical company BioPhausia. and today Medivir has a broad product portfolio with prescription pharmaceuticals in the Nordics.

Medivir's first product, the unique cold sore product Xerese®/Xerclear®, is launched in collaboration with GlaxoSmithKline to be sold OTC under the brand name ZoviDuo in Europe, Japan and Russia.

Medivir's IPO was in 1996 and currently the company has around 180 employees.

For more information about Medivir, please visit the Company's website: http://www.medivir.com

For more information about Medivir, please contact:

Medivir
Rein Piir, EVP Corporate Affairs & IR    
Direct: +46-8-440-6550 or:
Mobile: +46-708-537-292 

M:Communications
Europe: Mary-Jane Elliott, Amber Bielecka, Hollie Vile    
medivir@mcomgroup.com
+44(0)20-7920-2330



'/>"/>
SOURCE Medivir
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Symphogen Grants Exclusive Worldwide License of Phase II Oncology Drug Candidate Sym004 to Merck KGaA
2. ESTEVE Announces the Publication of Comprehensive Phase I Data for a Novel Oral, First-in-class New Chemical Entity (NCE),E-52862, a Sigma-1 Receptor Antagonist (S1RA) Being Developed for Pain
3. Sosei Group Corporation QVA149 Phase III Study Meets Primary Endpoint in Reducing Exacerbations in COPD Patients and Filings in EU and Japan by End of Year
4. Debiopharm Announces First Patient Enrolled in Phase III Study for the Rare Disease Central Precocious Puberty
5. Northwest Bio Receives Regulatory Approval To Proceed With Its Phase III Trial In The UK
6. Clinical Phase Ia Trial on MIV-711 Complete and Phase Ib Trial Commences
7. Lightlake Therapeutics Inc. Announces Positive Final Phase II Clinical Trial Results of Binge Eating Disorder Treatment
8. Robert Kirsner, MD, PhD, To Present Results For Phase 2b 6-Month Follow-Up Trial Of Unique Investigational Cell-Based Therapy For Venous Leg Ulcers
9. BioHealth Innovation, Inc. Caps Next Phase Of Development With Move To New Headquarters And Addition Of Staff
10. Sanofi and Regeneron Launch Comprehensive Phase 3 Clinical Program With LDL Cholesterol-Lowering PCSK9 Antibody
11. Convergence Pharmaceuticals Announces Successful Completion of Phase I for CNV2197944 and Plans Phase II Studies in Neuropathic Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Washington, USA (PRWEB) September 18, 2014 ... Representatives of a bill designed to stimulate development and ... jobs is being praised by leaders of SPIE, ... bill, the Revitalizing American Manufacturing and Innovation (RAMI) Act, ... The bill’s authors have said they are optimistic that ...
(Date:9/18/2014)... Mass. (PRWEB) September 18, 2014 A ... of an MRI scanner is currently being tested as ... and Women's Hospital in Boston with the aim of ... images, can make prostate cancer biopsies faster, more accurate, ... novel system also has the potential to deliver prostate ...
(Date:9/18/2014)... On Tuesday, Secretary of Energy Ernest ... for National Lab Day on the Hill. The event ... laboratory system. Durbin and Risch also formally launched the ... of the reach of the national labs as leaders ... some of our nation's most pressing challenges. , "The ...
(Date:9/18/2014)... 18, 2014 Research and Markets ... Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - ... offering. The global companion diagnostics market ... from 2014 to 2019. Factors such as rising need ... companion diagnostics by the pharmaceutical industry, support from regulatory ...
Breaking Biology Technology:House passage of high-tech manufacturing bill is move toward stronger economy, say SPIE leaders 2House passage of high-tech manufacturing bill is move toward stronger economy, say SPIE leaders 3Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 2Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 3Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 4Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 5Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 6Lab Day Highlight Labs' Contribution to U.S. Competitiveness and Innovation 2Lab Day Highlight Labs' Contribution to U.S. Competitiveness and Innovation 3Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 2Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 3
... ,Courage Under Fire, WORCESTER, Mass., Aug. 21 ... is proud to announced that Dr.,Robert Lanza, the ... been recognized for his research and contributions to ... of PharmaVOICE (cover,story July/August issue). Dr. Lanza is ...
... Efficiency, MINNEAPOLIS, Aug. 21 Vital ... provider of enterprise-wide advanced,visualization and analysis solutions, ... enterprise-wide advanced visualization and analysis product,solutions with ... 4.1. This,comprehensive package offers powerful advanced visualization ...
... Calif., Aug. 21 AMDL, Inc. (Amex:,ADL) announced today ... Company had net revenues of $2,413,501, an approximate increase ... had gross profits of $1,151,452,and incurred a net loss ... approximately $2,074,112 for depreciation, common stock,warrants and options issued. ...
Cached Biology Technology:Advanced Cell Technology's Dr. Robert Lanza Makes List of '100 Most Inspiring People in the Life-Sciences Industry' 2Advanced Cell Technology's Dr. Robert Lanza Makes List of '100 Most Inspiring People in the Life-Sciences Industry' 3Vital Images Releases Next Generation Enterprise-Wide Solutions Featuring Vitrea(R) 4.0 and ViTALConnect(R) 4.1 2Vital Images Releases Next Generation Enterprise-Wide Solutions Featuring Vitrea(R) 4.0 and ViTALConnect(R) 4.1 3Vital Images Releases Next Generation Enterprise-Wide Solutions Featuring Vitrea(R) 4.0 and ViTALConnect(R) 4.1 4AMDL Announces 2nd Quarter 2007 Operational Results 2
(Date:9/18/2014)... in DNA, tiny strands of nucleic acid that contain ... this genetic data, our DNA is copied into RNA ... perform tasks in our cells. , Several years ... Unlike all other known RNAs, this molecule is circular, ... abundant, little has been known about how they are ...
(Date:9/18/2014)... cheerful, happy-go-lucky characters, so you might expect that most ... In fact some dogs are distinctly more pessimistic than ... , "This research is exciting because it measures positive ... It offers researchers and dog owners an insight into ... Dr Melissa Starling, from the Faculty of Veterinary Science. ...
(Date:9/18/2014)... Elsevier, a world-leading provider of scientific, technical and ... Research Management Society (ARMS), recognized the academic research ... Scopus Young Researcher of the Year Awards. , ... National Convention Centre and in conjunction with the ... representing Australia,s and New Zealand,s scientific community. Guest ...
Breaking Biology News(10 mins):Scientists find how mysterious 'circular RNA' is formed, claim muscular dystrophy link 2Dogs can be pessimists too 2Dogs can be pessimists too 3Elsevier and Australasian Research Management Society award scientists at Scopus ceremony 2
... who are serious about wanting to reduce their "carbon footprint" ... may yield a large long-term benefit have one less ... concluded that in the United States, the carbon legacy and ... times more important than some of the other environmentally sensitive ...
... A collaborative team led by a University of Hawai,i at ... slug species that are of potential threat to the nation,s ... in the U.S. The July 2009 article in the ... Robert H. Cowie of the UH Manoa Center for Conservation ...
... that could let in more light and cut indoor ... Tropical regions without losing the cooling effect of shades. ... Engineering Systems Modelling and Simulation this month. ... Resources and Development, at the Asian Institute of Technology ...
Cached Biology News:Family planning a major environmental impact 2Opening a new window on daylight 2
... Transfer Sulfo SBED Protein:Protein Interaction Reagent ... Transfer has rapidly gained traction as an ... A growing number of publications feature the ... Reagent to study a variety of issues ...
... compact benchtop and stackable multi-function incubator. ... a large display screen to accurately ... circulation inside to evenly distribute temperature ... easily calibrated from the microprocessor controller. ...
... transfer is fast emerging as a powerful ... confirmation. Until now, only amino groups have ... transfer reagents such as our Sulfo-SBED. Sulfhydryl-reactive ... are exciting additions to the protein interaction ...
... designed as a high tech shaker for ... compensation allows high shaking speed even under ... therefore, faster growth and higher cell density. ... high reproducibility is critical Variable ...
Biology Products: